Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PARP1 | P09874 | 17/20 | 0.89 |
| ▸ | PIM1 | P11309 | 1/20 | 0.66 |
| ▸ | CSNK1D | P48730 | 1/20 | 0.66 |
| ▸ | HTR6 | P50406 | 2/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1319932 | 0.94 | PARP1 (1.00) | PARP1PIM1CSNK1DHTR6 | |
| SCHEMBL61115 | 0.93 | PARP1 (0.84) | PARP1PIM1CSNK1DHTR6 | |
| SCHEMBL14336535 | 0.91 | PARP1 (0.81) | PARP1PIM1CSNK1D | |
| SCHEMBL14336601 | 0.88 | PARP1 (0.79) | PARP1PIM1CSNK1D | |
| SCHEMBL1321187 | 0.87 | PARP1 (1.00) | PARP1PIM1CSNK1D | |
| SCHEMBL10035768 | 0.86 | PARP1 (0.91) | PARP1PIM1CSNK1D | |
| SCHEMBL12658579 | 0.85 | PARP1 (0.71) | PARP1PIM1CSNK1D | |
| SCHEMBL1317904 | 0.85 | PARP1 (1.00) | PARP1PIM1CSNK1D | |
| SCHEMBL2682991 | 0.85 | PARP1 (1.00) | PARP1PIM1CSNK1D | |
| SCHEMBL61262 | 0.84 | PARP1 (0.74) | PARP1PIM1CSNK1D |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090298837-A1 | poly(ADP-ribose) polymerase (PARP) inhibitors such as 9-[(Hydrozinooxy)carbonyl]-2,7-dihydro-6-methoxy 3H-pyrido-[4,3,2-de]phthalazin-3-one, used for treating neuron tissue damage resulting from ischemia and reperfusion injury, depression, inflammatory bowel disorders, arthritis, gout, pain and sepsis | EISAI CORPORATION OF NORTH AMERICA (US) | 2009-12-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090298837-A1 | poly(ADP-ribose) polymerase (PARP) inhibitors such as 9-[(Hydrozinooxy)carbonyl]-2,7-dihydro-6-methoxy 3H-pyrido-[4,3,2-de]phthalazin-3-one, used for treating neuron tissue damage resulting from ischemia and reperfusion injury, depression, inflammatory bowel disorders, arthritis, gout, pain and sepsis | PARP1, PARP2, NLRP3 | PARP1 1/4885PIM1 2223/4885CSNK1D 3850/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.